{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:48:08Z","timestamp":1780919288318,"version":"3.54.1"},"reference-count":99,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the National Science Centre of Poland","award":["UMO-2016\/23\/B\/NZ7\/01280"],"award-info":[{"award-number":["UMO-2016\/23\/B\/NZ7\/01280"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Treatment of negative symptoms and cognitive disorders in patients with schizophrenia is still a serious clinical problem. The aim of our study was to compare the efficacy of chronic administration of the atypical antipsychotic drug aripiprazole (7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl] butoxy}-3,4-dihydro-2(1H)-quinolinone; ARI) and the well-known antioxidant N-acetylcysteine (NAC) both in alleviating schizophrenia-like social and cognitive deficits and in reducing the decreases in the levels of the brain-derived neurotrophic factor (BDNF) in the prefrontal cortex (PFC) and hippocampus (HIP) of adult Sprague-Dawley rats, that have been induced by chronic administration of the model compound L-buthionine-(S, R)-sulfoximine (BSO) during the early postnatal development (p5\u2013p16). ARI was administered at doses of 0.1 and 0.3 mg\/kg while NAC at doses of 10 and 30 mg\/kg, alone or in combination. Administration of higher doses of ARI or NAC alone, or co-treatment with lower, ineffective doses of these drugs significantly improved social and cognitive performance as assessed in behavioral tests. Both doses of NAC and 0.3 mg\/kg of ARI increased the expression of BDNF mRNA in the PFC, while all doses of these drugs and their combinations enhanced the levels of BDNF protein in this brain structure. In the HIP, only 0,3 mg\/kg ARI increased the levels of both BDNF mRNA and its protein. These data show that in the rat BSO-induced neurodevelopmental model of schizophrenia, ARI and NAC differently modulated BDNF levels in the PFC and HIP.<\/jats:p>","DOI":"10.3390\/ijms23042125","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T22:44:47Z","timestamp":1644965087000},"page":"2125","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["N-Acetylcysteine and Aripiprazole Improve Social Behavior and Cognition and Modulate Brain BDNF Levels in a Rat Model of Schizophrenia"],"prefix":"10.3390","volume":"23","author":[{"given":"Zofia","family":"Rog\u00f3\u017c","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Sm\u0119tna Street, 31-343 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1359-8860","authenticated-orcid":false,"given":"Kinga","family":"Kami\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Sm\u0119tna Street, 31-343 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta Anna","family":"Lech","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Sm\u0119tna Street, 31-343 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9970-8548","authenticated-orcid":false,"given":"El\u017cbieta","family":"Lorenc-Koci","sequence":"additional","affiliation":[{"name":"Department of Neuro-Psychopharmacology, Maj Institute of Pharmacology, Polish Academy of Sciences, 12 Sm\u0119tna Street, 31-343 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.euroneuro.2005.04.009","article-title":"Size of burden of schizophrenia and psychotic disorders","volume":"15","author":"Salize","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4001563","article-title":"Phenotype of schizophrenia: A review and formulation","volume":"10","author":"Tamminga","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/YCO.0b013e3280ba4975","article-title":"Cognitive heterogeneity in schizophrenia","volume":"20","author":"Joyce","year":"2007","journal-title":"Curr. Opin. Psychiatry"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4088\/JCP.13065su1.06","article-title":"The early longitudinal course of cognitive deficits in schizophrenia","volume":"75","author":"Nuechterlein","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4088\/JCP.13065su1.02","article-title":"The longitudinal course of cognitive impairment in schizophrenia: An examination of data from premorbid through posttreatment phases of illness","volume":"75","author":"Keefe","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/mp.2012.47","article-title":"Pharmacological treatment of schizophrenia: A critical review of the pharmacology and clinical effects of current and future therapeutic agents","volume":"17","author":"Miyamoto","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/schbul\/sbn117","article-title":"Gene-environment interactions in schizophrenia: Review of epidemiological findings and future directions","volume":"34","author":"Rutten","year":"2008","journal-title":"Schizophr. Bull."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nature09563","article-title":"The environment and schizophrenia","volume":"468","author":"Kenis","year":"2010","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2173748","DOI":"10.1155\/2016\/2173748","article-title":"Gene \u00d7 environment interactions in schizophrenia: Evidence from genetic mouse models","volume":"2016","author":"Moran","year":"2016","journal-title":"Neural Plast."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.neuro.25.112701.142754","article-title":"Schizophrenia as a disorder of neurodevelopment","volume":"25","author":"Lewis","year":"2002","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ijdevneu.2010.10.003","article-title":"Childhood onset schizophrenia: Support for a progressive neurodevelopmental disorder","volume":"29","author":"Rapoport","year":"2011","journal-title":"Int. J. Dev. Neurosci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/mp.2012.23","article-title":"Neurodevelopmental model of schizophrenia: Update 2012","volume":"17","author":"Rapoport","year":"2012","journal-title":"Mol. Psychiatry"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/nrn2513","article-title":"Why do many psychiatric disorders emerge during adolescence?","volume":"9","author":"Paus","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/schbul\/sbr029","article-title":"Postnatal developmental trajectories of neural circuits in the primate prefrontal cortex: Identifying sensitive periods for vulnerability to schizophrenia","volume":"37","author":"Hoftman","year":"2011","journal-title":"Schizophr. Bull."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/schbul\/sbv065","article-title":"Targeting oxidative stress and aberrant critical period plasticity in the developmental trajectory to schizophrenia","volume":"41","author":"Do","year":"2015","journal-title":"Schizophr. Bull."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/nn.2647","article-title":"Animal models of neuropsychiatric disorders","volume":"13","author":"Nestler","year":"2010","journal-title":"Nat. Neurosci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fnmol.2019.00185","article-title":"NMDAR hypofunction animal models of schizophrenia","volume":"12","author":"Lee","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.bbr.2009.01.031","article-title":"Gestational methylazoxymethanol acetate administration: A developmental disruption model of schizophrenia","volume":"204","author":"Lodge","year":"2009","journal-title":"Behav. Brain Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pnpbp.2014.10.004","article-title":"Prenatal LPS-exposure--a neurodevelopmental rat model of schizophrenia--differentially affects cognitive functions, myelination and parvalbumin expression in male and female offspring","volume":"57","author":"Wischhof","year":"2015","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1155\/2006\/248387","article-title":"Altered glutathione redox state in schizophrenia","volume":"22","author":"Yao","year":"2006","journal-title":"Dis. Markers"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1046\/j.1460-9568.2000.00229.x","article-title":"Schizophrenia: Glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo","volume":"12","author":"Do","year":"2000","journal-title":"Eur. J. Neurosci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1089\/ars.2010.3453","article-title":"Magnetic resonance spectroscopy study of the antioxidant defense system in schizophrenia","volume":"15","author":"Matsuzawa","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1017\/S1461145710000805","article-title":"Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders","volume":"14","author":"Gawryluk","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1001\/jamapsychiatry.2018.3637","article-title":"Assessing brain metabolism with 7-T proton magnetic resonance spectroscopy in patients with first-episode psychosis","volume":"76","author":"Wang","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pnpbp.2018.08.006","article-title":"Antioxidant defense in schizophrenia and bipolar disorder: A meta-analysis of MRS studies of anterior cingulate glutathione","volume":"91","author":"Das","year":"2019","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Palaniyappan, L., Park, M.T.M., Jeon, P., Limongi, R., Yang, K., Sawa, A., and Th\u00e9berge, J. (2021). Is there a glutathione centered redox dysregulation subtype of schizophrenia?. Antioxidants, 10.","DOI":"10.20944\/preprints202109.0449.v1"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1753-4887.1992.tb01298.x","article-title":"Buthionine sulfoximine, an experimental tool to induce glutathione deficiency: Elucidation of glutathione and ascorbate in their role as antioxidants","volume":"50","author":"Broquist","year":"1992","journal-title":"Nutr. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0009-2797(97)00146-4","article-title":"Glutathione: An overview of biosynthesis and modulation","volume":"111\u2013112","author":"Anderson","year":"1998","journal-title":"Chem. Biol. Interact."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.nbd.2007.03.001","article-title":"Transitory glutathione deficit during brain development induces cognitive impairment in juvenile and adult rats: Relevance to schizophrenia","volume":"26","author":"Cabungcal","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"G\u00f3rny, M., Wnuk, A., Kami\u0144ska, A., Kami\u0144ska, K., Chwatko, G., Bilska-Wilkosz, A., Iciek, M., Kajta, M., Rog\u00f3\u017c, Z., and Lorenc-Koci, E. (2019). Glutathione deficiency and alterations in the sulfur amino acids homeostasis during early postnatal development as potential triggering factors for schizophrenia-like behavior in adult rats. Molecules, 24.","DOI":"10.3390\/molecules24234253"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Lech, M.A., Le\u015bkiewicz, M., Kami\u0144ska, K., Rog\u00f3\u017c, Z., and Lorenc-Koci, E. (2021). Glutathione deficiency during early postnatal development causes schizophrenia-like symptoms and a reduction in BDNF levels in the cortex and hippocampus of adult Sprague-Dawley rats. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126171"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"9235","DOI":"10.1073\/pnas.93.17.9235","article-title":"Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects","volume":"93","author":"Laruelle","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1073\/pnas.94.6.2569","article-title":"Schizophrenia is associated with elevated ampheta mine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method","volume":"94","author":"Breier","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1176\/ajp.155.6.761","article-title":"Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort","volume":"155","author":"Gil","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"15763","DOI":"10.1074\/jbc.M511767200","article-title":"Evidence that DNA (cytosine-5) methyltransferase regulates synaptic plasticity in the hippocampus","volume":"281","author":"Levenson","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1038\/nn.2666","article-title":"DNA methylation and memory formation","volume":"13","author":"Day","year":"2010","journal-title":"Nat. Neurosci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/mp.2009.138","article-title":"Brain weight in males is correlated with DNA methylation at IGF2","volume":"15","author":"Pidsley","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/1073858415579635","article-title":"DNA methylation in memory formation: Emerging insights","volume":"21","author":"Heyward","year":"2015","journal-title":"Neuroscientist"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s007020050040","article-title":"Neurotrophic factors and the maldevelopmental hypothesis of schizophrenic psychoses","volume":"105","author":"Thome","year":"1998","journal-title":"J. Neural Transm"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.mp.4001637","article-title":"BDNF in schizophrenia, depression and corresponding animal models","volume":"10","author":"Angelucci","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000111562","article-title":"Brain-derived neurotropic factor\/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia","volume":"16","author":"Pillai","year":"2008","journal-title":"Neurosignals"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1124\/pr.111.005108","article-title":"Brain-derived neurotrophic factor and neuropsychiatric disorders","volume":"64","author":"Autry","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/sj.mp.4001308","article-title":"Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia","volume":"8","author":"Weickert","year":"2003","journal-title":"Mol. Psychiatry"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1523\/JNEUROSCI.4035-04.2005","article-title":"Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia","volume":"25","author":"Hashimoto","year":"2005","journal-title":"J. Neurosci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0920-9964(00)00084-0","article-title":"Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses","volume":"52","author":"Durany","year":"2001","journal-title":"Schizophr. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/sj.mp.4000718","article-title":"Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients","volume":"5","author":"Takahashi","year":"2000","journal-title":"Mol. Psychiatry"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0278-5846(03)00112-X","article-title":"Immunohistochemical study of brain-derived neurotrophic factor and its receptor, TrkB, in the hippocampal formation of schizophrenic brains","volume":"27","author":"Iritani","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/npp.1993.44","article-title":"Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: A potential animal model of schizophrenia","volume":"9","author":"Lipska","year":"1993","journal-title":"Neuropsychopharmacology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbr.2008.11.039","article-title":"The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia","volume":"204","author":"Tseng","year":"2009","journal-title":"Behav. Brain Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1460-9568.2001.01633.x","article-title":"BDNF mRNA expression in rat hippocampus and prefrontal cortex: Effects of neonatal ventral hippocampal damage and antipsychotic drugs","volume":"14","author":"Lipska","year":"2001","journal-title":"Eur. J. Neurosci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0006-8993(02)03176-1","article-title":"Brain-derived neurotrophic factor (BDNF) mRNA in rats with neonatal ibotenic acid lesions of the ventral hippocampus","volume":"956","author":"Ashe","year":"2002","journal-title":"Brain Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0892-0362(01)00214-8","article-title":"Long-lasting effects of prenatal MAM exposure on water maze response in aged rats: Correlation with altered brain development and neurotrophins\u2019 expression","volume":"24","author":"Fiore","year":"2002","journal-title":"Neurotoxicol. Teratol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/1097-4547(20000615)60:6<783::AID-JNR11>3.0.CO;2-M","article-title":"Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration","volume":"60","author":"Angelucci","year":"2000","journal-title":"J. Neurosci. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/jnr.10440","article-title":"Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs","volume":"71","author":"Bai","year":"2003","journal-title":"J. Neurosci. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.neulet.2006.03.028","article-title":"Effects of quetiapine on the brain-derived neurotrophic factor expression in the hippocampus and neocortex of rats","volume":"402","author":"Park","year":"2006","journal-title":"Neurosci. Lett."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jpsychires.2008.05.010","article-title":"Differential effects of ziprosidone and haloperidol on immobilization stress-induced mRNA expression in the hippocampus and neocortex of rats","volume":"43","author":"Park","year":"2009","journal-title":"J. Psychiatr. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1503\/jpn.100057","article-title":"N-acetylcysteine in psychiatry: Current therapeutic evidence and potential mechanisms of action","volume":"36","author":"Dean","year":"2011","journal-title":"J. Psychiatry Neurosci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/1028415X.2018.1478766","article-title":"Improvement of cognitive function in schizophrenia with N-acetylcysteine: A theoretical review","volume":"23","author":"Yolland","year":"2020","journal-title":"Nutr. Neurosci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.pharep.2019.04.007","article-title":"Co-treatment with antidepressants and aripiprazole reversed the MK-801-induced some negative symptoms of schizophrenia in rats","volume":"71","author":"Hereta","year":"2019","journal-title":"Pharmacol. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"112769","DOI":"10.1016\/j.bbr.2020.112769","article-title":"Effect of combined treatment with aripiprazole and antidepressants on the MK-801-induced deficits in recognition memory in novel recognition test and on the release of monoamines in the rat frontal cortex","volume":"393","author":"Hereta","year":"2020","journal-title":"Behav. Brain Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","article-title":"The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor","volume":"441","author":"Jordan","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1742-1241.2003.tb11397.x","article-title":"Aripiprazole: A review of its pharmacology and clinical use","volume":"57","author":"Taylor","year":"2003","journal-title":"Int. J. Clin. Pract."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1185\/030079903125002919","article-title":"Focus on aripiprazole","volume":"20","author":"Green","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.neuropharm.2005.05.013","article-title":"Effects of novel antipsychotics with mixed D(2) antagonist\/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat","volume":"49","author":"Kleven","year":"2005","journal-title":"Neuropharmacology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.neuropharm.2011.08.031","article-title":"Dopamine D2 and serotonin 5-HT1A receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission","volume":"62","author":"Tanahashi","year":"2012","journal-title":"Neuropharmacology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Torrisi, S.A., Laudani, S., Contarini, G., De Luca, A., Geraci, F., Manag\u00f2, F., Papaleo, F., Salomone, S., Drago, F., and Leggio, G.M. (2020). Dopamine, cognitive impairments and second-generation antipsychotics: From mechanistic advances to more personalized treatments. Pharmaceuticals, 13.","DOI":"10.3390\/ph13110365"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0149-2918(04)90066-5","article-title":"Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability","volume":"26","author":"DeLeon","year":"2004","journal-title":"Clin. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.neulet.2010.01.010","article-title":"Effects of aripiprazole on MK-801-induced prepulse inhibition deficits and mitogen-activated protein kinase signal transduction pathway","volume":"471","author":"Ishii","year":"2010","journal-title":"Neurosci. Lett."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00213-010-2065-7","article-title":"Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: Relationship with glutamate release in the medial prefrontal cortex","volume":"214","author":"Carli","year":"2011","journal-title":"Psychopharmacology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.nlm.2007.08.018","article-title":"BDNF: A key regulator for protein synthesis-dependent LTP and long-term memory?","volume":"89","author":"Lu","year":"2008","journal-title":"Neurobiol. Learn. Mem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/archneur.63.10.1372","article-title":"Cognitive dysfunction in schizophrenia: Convergence of gamma-aminobutyric acid and glutamate alterations","volume":"63","author":"Lewis","year":"2006","journal-title":"Arch. Neurol."},{"key":"ref_74","first-page":"4","article-title":"Glutamatergic theories of schizophrenia","volume":"47","author":"Javitt","year":"2010","journal-title":"Isr. J. Psychiatry Relat. Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/wps.20693","article-title":"Dopamine and glutamate in schizophrenia: Biology, symptoms and treatment","volume":"19","author":"McCutcheon","year":"2020","journal-title":"World Psychiatry"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/0006-8993(79)90306-8","article-title":"Glutamate as a CNS transmitter. I. Evaluation of glucose and glutamine as precursors for the synthesis of preferentially released glutamate","volume":"168","author":"Hamberger","year":"1979","journal-title":"Brain Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0301-0082(90)90013-7","article-title":"Metabolism and role of glutamate in mammalian brain","volume":"35","author":"Silver","year":"1990","journal-title":"Prog. Neurobiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrd2462","article-title":"Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders","volume":"7","author":"Sanacora","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"9192","DOI":"10.1523\/JNEUROSCI.1198-07.2007","article-title":"Excitatory synaptic transmission persists independently of the glutamate-glutamine cycle","volume":"27","author":"Kam","year":"2007","journal-title":"J. Neurosci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.bbrc.2011.04.087","article-title":"Glutathione is a physiologic reservoir of neuronal glutamate","volume":"409","author":"Koga","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1073\/pnas.1817885116","article-title":"The glutathione cycle shapes synaptic glutamate activity","volume":"116","author":"Sedlak","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1528-1167.2007.01295.x","article-title":"Timing of the developmental switch in GABA(A) mediated signaling from excitation to inhibition in CA3 rat hippocampus using gramicidin perforated patch and extracellular recordings","volume":"48","author":"Tyzio","year":"2007","journal-title":"Epilepsia"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10571-006-9062-8","article-title":"Glutamate and schizophrenia: Beyond the dopamine hypothesis","volume":"26","author":"Coyle","year":"2006","journal-title":"Cell Mol. Neurobiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1124\/pr.107.00107","article-title":"Antipsychotic drugs: Comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection","volume":"60","author":"Lieberman","year":"2008","journal-title":"Pharmacol. Rev."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.biopsych.2008.03.004","article-title":"N-acetyl cysteine as a glutathione precursor for schizophrenia\u2014a double-blind, randomized, placebo-controlled trial","volume":"64","author":"Berk","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/WNF.0000000000000001","article-title":"N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: A randomized, double-blind, placebo-controlled study","volume":"36","author":"Farokhnia","year":"2013","journal-title":"Clin. Neuropharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.schres.2018.03.012","article-title":"Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders","volume":"199","author":"Breier","year":"2018","journal-title":"Schizophr. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/schbul\/sbx093","article-title":"N-acetylcysteine in a double-blind randomized placebo-controlled trial: Toward biomarker-guided treatment in early psychosis","volume":"44","author":"Conus","year":"2018","journal-title":"Schizophr. Bull."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1017\/S0033291716002932","article-title":"Cognitive effects of adjunctive N-acetyl cysteine in psychosis","volume":"47","author":"Dodd","year":"2017","journal-title":"Psychol. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.neubiorev.2017.04.013","article-title":"The effect of N-acetylcysteine (NAC) on human cognition\u2014A systematic review","volume":"78","author":"Skvarc","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1038\/sj.npp.1301532","article-title":"Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine","volume":"33","author":"Baker","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/jnc.13348","article-title":"Main path and byways: Non-vesicular glutamate release by system xc(-) as an important modifier of glutamatergic neurotransmission","volume":"135","author":"Massie","year":"2015","journal-title":"J. Neurochem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"9134","DOI":"10.1523\/JNEUROSCI.22-20-09134.2002","article-title":"The origin and neuronal function of in vivo nonsynaptic glutamate","volume":"22","author":"Baker","year":"2002","journal-title":"J. Neurosci."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Fukuyama, K., Hasegawa, T., and Okada, M. (2018). Cystine\/glutamate antiporter and aripiprazole compensate NMDA antagonist-induced dysfunction of thalamocortical L-glutamatergic transmission. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113645"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1192\/j.eurpsy.2021.13","article-title":"EPA guidance on treatment of negative symptoms in schizophrenia","volume":"64","author":"Galderisi","year":"2021","journal-title":"Eur. Psychiatry"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1007\/s43440-021-00318-z","article-title":"Impact of repeated co-treatment with escitalopram and aripiprazole on the schizophrenia-like behaviors and BDNF mRNA expression in the adult Sprague-Dawley rats exposed to glutathione deficit during early postnatal development of the brain","volume":"73","author":"Lech","year":"2021","journal-title":"Pharmacol. Rep."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/17425255.2017.1251580","article-title":"N-acetylcysteine in the treatment of psychiatric disorders: Current status and future prospects","volume":"13","author":"Minarini","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/eip.13149","article-title":"N-acetylcysteine for depression and glutamate changes in the left prefrontal cortex in adolescents and young adults at risk for bipolar disorder: A pilot study","volume":"16","author":"Nery","year":"2022","journal-title":"Early Interv. Psychiatry"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.pharep.2015.04.006","article-title":"The effect of combined treatment with risperidone and antidepressants on the MK-801-induced deficits in the social interaction test in rats","volume":"67","year":"2015","journal-title":"Pharmacol. Rep."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/4\/2125\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:19:46Z","timestamp":1760134786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/4\/2125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":99,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["ijms23042125"],"URL":"https:\/\/doi.org\/10.3390\/ijms23042125","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,15]]}}}